Factor Xa

Factor Xa製品

  • All (8)
  • Factor Xa阻害剤 (8)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S1593 Apixaban Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
Basic Res Cardiol, 2023, 118(1):31
Thromb Res, 2023, 227:17-24
J Neuroinflammation, 2022, 19(1):138
S3002 Rivaroxaban Rivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM in cell-free assays, respectively. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (IC50 >20 μM).
Basic Res Cardiol, 2023, 118(1):31
Thromb Res, 2023, 227:17-24
Brain Behav Immun Health, 2023, 28:100593
S1346 Heparin sodium Heparin sodium, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities associated with its interaction with diverse proteins. Heparin is used as an anticoagulant primarily through its interaction with AT III by enhancing AT-IIImediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin prevents the induction of autophagy.
Ecotoxicol Environ Saf, 2023, 252:114608
STAR Protoc, 2023, 4(1):102122
Adv Sci (Weinh), 2022, 9(30):e2203388
S7280 Edoxaban tosylate Monohydrate Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.
J Thromb Haemost, 2020, 18(8):1866-1873
Viruses, 2020, 10;12(6):E629
J Chromatogr B Analyt Technol Biomed Life Sci, 2020, 1146:122121
S4429 Edoxaban Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
Cancer Lett, 2023, 553:215983
Thromb Res, 2023, 227:17-24
J Thromb Haemost, 2020, 18(8):1866-1873
S5388 Betrixaban Betrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S5389 Betrixaban maleate Betrixaban maleate is the maleate salt form of Betrixaban, which is a Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S3736 Fondaparinux Sodium (Org 31540) Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.
S1593 Apixaban Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
Basic Res Cardiol, 2023, 118(1):31
Thromb Res, 2023, 227:17-24
J Neuroinflammation, 2022, 19(1):138
S3002 Rivaroxaban Rivaroxaban is a direct inhibitor of Factor Xa with Ki and IC50 of 0.4 nM and 0.7 nM in cell-free assays, respectively. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (IC50 >20 μM).
Basic Res Cardiol, 2023, 118(1):31
Thromb Res, 2023, 227:17-24
Brain Behav Immun Health, 2023, 28:100593
S1346 Heparin sodium Heparin sodium, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities associated with its interaction with diverse proteins. Heparin is used as an anticoagulant primarily through its interaction with AT III by enhancing AT-IIImediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin prevents the induction of autophagy.
Ecotoxicol Environ Saf, 2023, 252:114608
STAR Protoc, 2023, 4(1):102122
Adv Sci (Weinh), 2022, 9(30):e2203388
S7280 Edoxaban tosylate Monohydrate Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.
J Thromb Haemost, 2020, 18(8):1866-1873
Viruses, 2020, 10;12(6):E629
J Chromatogr B Analyt Technol Biomed Life Sci, 2020, 1146:122121
S4429 Edoxaban Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
Cancer Lett, 2023, 553:215983
Thromb Res, 2023, 227:17-24
J Thromb Haemost, 2020, 18(8):1866-1873
S5388 Betrixaban Betrixaban is a new, long-acting, oral and selective Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S5389 Betrixaban maleate Betrixaban maleate is the maleate salt form of Betrixaban, which is a Factor Xa inhibitor that decreases prothrombinase activity and thrombin generation.
PLoS One, 2022, 17(1):e0262482
S3736 Fondaparinux Sodium (Org 31540) Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.

Factor Xa阻害剤の選択性比較

Factor Xaシグナル伝達経路

Factor Xaシグナル伝達経路
Tags: Factor Xa inhibitor|Factor Xa agonist|Factor Xa activator|Factor Xa inducer|Factor Xa antagonist|Factor Xa signaling pathway|Factor Xa assay kit